Immugenyx, a wholly-owned subsidiary of Hemogenyx Pharmaceuticals, has developed a new type of humanised mouse called Advanced peripheral blood Hematopoietic Chimera (ApbHC) to help develop treatments against unknown human-specific pathogens.

Initially developed as a research and development tool to investigate mature blood cell populations such as human T-cells, B-cells and antibody-producing plasma cells, ApbHC presents various advantages compared to other mouse models.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Hemogenyx established Immugenyx to develop and commercialise its advanced Hematopoietic Chimeras (AHC) or humanised mice.

The company has demonstrated that the new mouse model has the potential to be used for testing multi-specific antibodies, including its own bi-specific CDX antibody to remove acute myeloid leukaemia (AML) and the conditioning of patients for bone marrow transplantation.

Additionally, ApbHC may be used to develop and test new cell therapies involving immune cell reprogramming, such as CAR-T.

Hemogenyx Pharmaceuticals CEO Vladislav Sandler said: “The ApbHC has allowed us to rapidly obtain in vivo data on the efficacy of our CDX antibodies against AML.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are actively developing and expanding the potential use of the ApbHC for disease modelling, the development of new therapeutics, and biodefense applications.

“Our ApbHC has also generated significant interest from third parties who also see its potential for disease modelling and drug development.”

Furthermore, the ApbHC can potentially be used for the modelling of autoimmune diseases, such as Systemic Lupus Erythematosus (aka Lupus).

It could also be used as a tool for the development and/or isolation of human antibodies against unknown human-specific pathogens.